Are specialty pharma CEOs worth their salt?

Carly Helfand

drugmakers often find treatments scrutinized, with critics wondering if they're their sometimes high price tags. But what about their CEOs?

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS